North American Vasovagal Pacemaker Study: study design and organization.
The North American Vasovagal Pacemaker Study is an ongoing multicenter randomized, clinical trial that assesses the efficacy of dual chamber pacing utilizing rate drop sensing in patients with frequent syncopal spells. Patients are eligible if they have had at least six syncopal spells and a positive tilt table test, or a recurrence of syncope within 6 months of a positive tilt test. The tilt table test must have provoked a relative bradycardia. Patients are randomized to receive a Medtronic Thera DR with rate drop sensing, or to continue on their usual therapy. All patients complete a log of their presyncopal and syncopal spells daily, and are contacted every 2 months. The primary outcome measure is the time to the first recurrence of syncope. The goal of the main study is to recruit 284 patients in 3 years with a final fourth year of follow-up; this will result in an 80% chance of detecting a 30% reduction in the risk of syncope. A pilot study is under way with the aim to recruit 60 patients over a period of 2 years with a final third year of follow-up. Recruitment began in July 1995 and 47 patients have been enrolled to date.
Sheldon
R S
RS
Cardiovascular Research Group, University of Calgary, Alberta, Canada.
Gent
M
M
Roberts
R S
RS
Connolly
S J
SJ
D001919:Bradycardia / Q000503:physiopathology; D002304:Cardiac Pacing, Artificial / Q000379:methods; D004867:Equipment Design; D005500:Follow-Up Studies; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D008499:Medical Records; D009656:North America; D010138:Pacemaker, Artificial; D018579:Patient Selection; D010865:Pilot Projects; D012008:Recurrence; D012107:Research Design; D012307:Risk Factors; D018401:Sample Size; D013575:Syncope / Q000503:physiopathology; D019462:Syncope, Vasovagal / Q000503:physiopathology / Q000628:therapy*; D018667:Tilt-Table Test; D016896:Treatment Outcome